Compare Dr. Reddys with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs IPCA LABS - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB IPCA LABS DR. REDDYS LAB/
IPCA LABS
 
P/E (TTM) x 21.7 22.5 96.4% View Chart
P/BV x 3.2 4.4 74.4% View Chart
Dividend Yield % 0.7 0.1 676.7%  

Financials

 DR. REDDYS LAB   IPCA LABS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
IPCA LABS
Mar-18
DR. REDDYS LAB/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,875695 413.4%   
Low Rs1,888400 472.0%   
Sales per share (Unadj.) Rs930.2260.2 357.5%  
Earnings per share (Unadj.) Rs117.419.0 618.9%  
Cash flow per share (Unadj.) Rs185.833.1 562.0%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.80.2 460.0%  
Book value per share (Unadj.) Rs844.4213.0 396.4%  
Shares outstanding (eoy) m166.07126.20 131.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.1 121.6%   
Avg P/E ratio x20.328.9 70.3%  
P/CF ratio (eoy) x12.816.6 77.4%  
Price / Book Value ratio x2.82.6 109.7%  
Dividend payout %17.05.3 323.1%   
Avg Mkt Cap Rs m395,49669,120 572.2%   
No. of employees `00022.013.3 165.7%   
Total wages/salary Rs m33,5627,359 456.1%   
Avg. sales/employee Rs Th7,032.82,477.4 283.9%   
Avg. wages/employee Rs Th1,527.9555.2 275.2%   
Avg. net profit/employee Rs Th887.7180.6 491.4%   
INCOME DATA
Net Sales Rs m154,48232,836 470.5%  
Other income Rs m3,375418 807.4%   
Total revenues Rs m157,85733,254 474.7%   
Gross profit Rs m31,7824,505 705.5%  
Depreciation Rs m11,3481,777 638.5%   
Interest Rs m889240 370.1%   
Profit before tax Rs m22,9202,905 788.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858511 754.8%   
Profit after tax Rs m19,5002,394 814.5%  
Gross profit margin %20.613.7 150.0%  
Effective tax rate %16.817.6 95.7%   
Net profit margin %12.67.3 173.1%  
BALANCE SHEET DATA
Current assets Rs m111,10119,455 571.1%   
Current liabilities Rs m58,97310,076 585.3%   
Net working cap to sales %33.728.6 118.1%  
Current ratio x1.91.9 97.6%  
Inventory Days Days7998 81.1%  
Debtors Days Days9467 140.7%  
Net fixed assets Rs m101,24520,260 499.7%   
Share capital Rs m830252 328.8%   
"Free" reserves Rs m139,40626,633 523.4%   
Net worth Rs m140,23626,886 521.6%   
Long term debt Rs m22,0002,340 940.1%   
Total assets Rs m224,65641,173 545.6%  
Interest coverage x26.813.1 204.5%   
Debt to equity ratio x0.20.1 180.2%  
Sales to assets ratio x0.70.8 86.2%   
Return on assets %9.16.4 141.8%  
Return on equity %13.98.9 156.1%  
Return on capital %14.910.8 138.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m88,67315,642 566.9%   
Fx outflow Rs m19,1044,884 391.2%   
Net fx Rs m69,56910,759 646.6%   
CASH FLOW
From Operations Rs m28,7043,411 841.4%  
From Investments Rs m-7,727-1,354 570.7%  
From Financial Activity Rs m-21,326-1,304 1,635.3%  
Net Cashflow Rs m-314753 -41.7%  

Share Holding

Indian Promoters % 25.5 45.9 55.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.4 47.4%  
FIIs % 35.3 25.3 139.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.4 87.9%  
Shareholders   75,885 36,892 205.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 18, 2019 12:25 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - DIVIS LABORATORIES COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS